Professor Eric Gowans

Eric Gowans
NHMRC Senior Research Fellow
Adelaide Medical School
Faculty of Health and Medical Sciences

Professor Eric Gowans.

Professor Eric Gowans is an experienced molecular virologist who has worked on several of the hepatitis viruses throughout his career. His PhD studies examined the replication and pathogenesis of hepatitis B virus and later he worked on hepatitis delta virus. He has worked on hepatitis C virus (HCV) since the virus was discovered. More recently, he has worked on DNA and recombinant viral vectors as potential vaccines for human immunodeficiency virus (HIV) and HCV.

Connect with me

Professor Eric Gowans

Professor Eric Gowans.

Professor Eric Gowans is an experienced molecular virologist who has worked on several of the hepatitis viruses throughout his career. His PhD studies examined the replication and pathogenesis of hepatitis B virus and later he worked on hepatitis delta virus. He has worked on hepatitis C virus (HCV) since the virus was discovered. More recently, he has worked on DNA and recombinant viral vectors as potential vaccines for human immunodeficiency virus (HIV) and HCV.

Professor Eric Gowans is an experienced molecular virologist who has worked on several of the hepatitis viruses throughout his career. His PhD studies examined the replication and pathogenesis of hepatitis B virus and later he worked on hepatitis delta virus. He has worked on hepatitis C virus (HCV) since the virus was discovered. More recently, he has worked on DNA and recombinant viral vectors as potential vaccines for human immunodeficiency virus (HIV) and HCV.

For more information please follow the link:

Eric Gowans



Date Position Institution name
2010 Senior Research Fellow University of Adelaide, Adelaide
2008 - 2009 Executive Director Women's & Children's Health Research Institute, North Adelaide


Date Institution name Country Title
University of South Australia, Adelaide Australia M. App. Sc.
Napier College United Kingdom Fellow of Institute of Medical Laboratory Science
University of Adelaide, Adelaide Australia PhD

Research Interests

Immunology and Infection, Translational Health Outcomes


Year Citation
2017 Wijesundara, D., Yu, W., Quah, B., Eldi, P., Hayball, J., Diener, K. ... Grubor-Bauk, B. (2017). Cytolytic DNA vaccine encoding lytic perforin augments the maturation of- and antigen presentation by- dendritic cells in a time-dependent manner. Scientific Reports, 7, 1, -.
2017 Tomusange, K., Wijesundara, D., Gowans, E. & Grubor-Bauk, B. (2017). Human rhinovirus-A1 as an expression vector. Methods in molecular biology (Clifton, N.J.), 1581, 181-201.
2017 Wijesundara, D., Ranasinghe, C., Grubor-Bauk, B. & Gowans, E. (2017). Emerging targets for developing T cell-mediated vaccines for human immunodeficiency virus (HIV)-1. Frontiers in Microbiology, 8, OCT, -.
2016 Grubor-Bauk, B., Yu, W., Wijesundara, D., Gummow, J., Garrod, T., Brennan, A. ... Gowans, E. (2016). Intradermal delivery of DNA encoding HCV NS3 and perforin elicits robust cell-mediated immunity in mice and pigs. Gene Therapy, 23, 1, 26-37.
2016 Tomusange, K., Wijesundara, D., Gummow, J., Garrod, T., Li, Y., Gray, L. ... Gowans, E. (2016). A HIV-Tat/C4-binding protein chimera encoded by a DNA vaccine is highly immunogenic and contains acute EcoHIV infection in mice. Scientific Reports, 6, 1, 29131-1-29131-10.
2016 Tomusange, K., Wijesundara, D., Gummow, J., Wesselingh, S., Suhrbier, A., Gowans, E. & Grubor-Bauk, B. (2016). Mucosal vaccination with a live recombinant rhinovirus followed by intradermal DNA administration elicits potent and protective HIV-specific immune responses. Scientific Reports, 6, 1, 36658 -1-36658-11.
2016 Earnest-Silveira, L., Chua, B., Chin, R., Christiansen, D., Johnson, D., Herrmann, S. ... Torresi, J. (2016). Characterization of a hepatitis C virus-like particle vaccine produced in a human hepatocyte-derived cell line. Journal of General Virology, 97, 8, 1865-1876.
2016 Earnest-Silveira, L., Christiansen, D., Herrmann, S., Ralph, S., Das, S., Gowans, E. & Torresi, J. (2016). Large scale production of a mammalian cell derived quadrivalent hepatitis C virus like particle vaccine. Journal of Virological Methods, 236, 87-92.
2016 Jorritsma, S., Gowans, E., Grubor-Bauk, B. & Wijesundara, D. (2016). Delivery methods to increase cellular uptake and immunogenicity of DNA vaccines. Vaccine, 34, 46, 5488-5494.
2016 Kumar, A., Das, S., Mullick, R., Lahiri, P., Tatineni, R., Goswami, D. ... Das, S. (2016). Immune responses against hepatitis C virus genotype 3a virus-like particles in mice: a novel VLP prime-adenovirus boost strategy. Vaccine, 34, 8, 1115-1125.
2015 Gummow, J., Li, Y., Yu, W., Garrod, T., Wijesundara, D., Brennan, A. ... Gowans, E. (2015). A multiantigenic DNA vaccine that induces broad hepatitis C virus-specific T-Cell responses in mice. J. Ou (Ed.). Journal of Virology, 89, 15, 7991-8002.
2015 Tomusange, K., Yu, W., Suhrbier, A., Wijesundara, D., Grubor-Bauk, B. & Gowans, E. (2015). Engineering human rhinovirus serotype-A1 as a vaccine vector. Virus Research, 203, 72-76.
2015 Li, S., Plebanski, M., Smooker, P. & Gowans, E. (2015). Editorial: Why vaccines to HIV, HCV, and malaria have so far failed-challenges to developing vaccines against immunoregulating pathogens. Frontiers in Microbiology, 6, NOV, -.
2014 Yu, W., Grubor-Bauk, B., Gargett, T., Garrod, T. & Gowans, E. (2014). A novel challenge model to evaluate the efficacy of hepatitis C virus vaccines in mice. Vaccine, 32, 27, 3409-3416.
2014 Garrod, T., Grubor-Bauk, B., Yu, S., Gargett, T. & Gowans, E. J. (2014). Encoded novel forms of HSP70 or a cytolytic protein increase DNA vaccine potency. Human Vaccines and Immunotherapeutics, 10, 9, 2679-2683.
2014 Yu, W., Grubor-Bauk, B., Mullick, R., Das, S. & Gowans, E. (2014). Immunocompetent mouse models to evaluate intrahepatic T cell responses to HCV vaccines. Human vaccines & immunotherapeutics, 10, 12, 3576-3578.
2014 Garrod, T., Grubor-Bauk, B., Gargett, T., Li, Y., Miller, D., Yu, W. ... Gowans, E. (2014). DNA vaccines encoding membrane-bound or secreted forms of heat shock protein 70 exhibit improved potency. European Journal of Immunology, 44, 7, 1992-2002.
2014 Gargett, T., Grubor-Bauk, B., Miller, D., Garrod, T., Yu, S., Wesselingh, S. ... Gowans, E. (2014). Increase in DNA vaccine efficacy by virosome delivery and co-expression of a cytolytic protein. Clinical and Translational Immunology, 3, 6, e18-1-e18-7.
2014 Garrod, T., Grubor-Bauk, B., Yu, S., Gargett, T. & Gowans, E. (2014). Encoded novel forms of HSP70 or a cytolytic protein increase DNA vaccine potency.. Human vaccines & immunotherapeutics, 10, 9, -.
2014 Garrod, T., Gargett, T., Yu, W., Major, L., Burrell, C., Wesselingh, S. ... Gowans, E. (2014). Loss of long term protection with the inclusion of HIV pol to a DNA vaccine encoding gag. Virus Research, 192, 25-33.
2014 Gargett, T., Grubor-Bauk, B., Garrod, T., Yu, W., Miller, D., Major, L. ... Gowans, E. (2014). Induction of antigen-positive cell death by the expression of Perforin, but not DTa, from a DNA vaccine enhances the immune response. Immunology and Cell Biology, 92, 4, 359-367.
2014 Beard, M., Ffrench, R., Gowans, E., Helbig, K., Eyre, N., Douglas, M. ... Drummer, H. (2014). A summary of the 20th International Symposium on Hepatitis C Virus and Related Viruses. Gastroenterology, 147, 1, e1-e4.
2013 Li, S., Lefranc, M., Miles, J., Alamyar, E., Giudicelli, V., Duroux, P. ... Gowans, E. (2013). IMGT/HighV QUEST paradigm for T cell receptor IMGT clonotype diversity and next generation repertoire immunoprofiling. Nature Communications, 4, 1-13.
2013 Gouklani, H., Beyer, C., Drummer, H., Gowans, E., Netter, H. & Haqshenas, G. (2013). Identification of specific regions in hepatitis C virus core, NS2 and NS5A that genetically interact with p7 and co-ordinate infectious virus production. Journal of Viral Hepatitis, 20, 4, e66-e71.
2012 Gouklani, H., Bull, R. A., Beyer, C., Coulibaly, F., Gowans, E. J., Drummer, H. E. ... Haqshenas, G. (2012). Hepatitis C virus nonstructural protein 5B is involved in virus morphogenesis. Journal of Virology, 86, 9, 5080-5088.
2012 Li, S., Roberts, S., Plebanski, M., Gouillou, M., Spelman, T., Latour, P. ... Gowans, E. (2012). Induction of multi-functional T cells in a phase I clinical trial of dendritic cell immunotherapy in Hepatitis C virus infected individuals. PLoS One, 7, 8, 1-7.
2012 Gorzin, A., Ramsland, P., Tachedjian, G. & Gowans, E. (2012). Identification of residues involved in NS2 homodimerization and elucidation of their impact on the HCV life cycle. Journal of Viral Hepatitis, 19, 3, 189-198.
2012 Wong, S., Haqshenas, G., Gowans, E. & MacKenzie, J. (2012). The dengue virus M protein localises to the endoplasmic reticulum and forms oligomers. FEBS Letters, 586, 7, 1032-1037.
2011 Wong, S. -. S., Chebib, M., Haqshenas, G., Loveland, B. & Gowans, E. J. (2011). Dengue virus PrM/M proteins fail to show pH-dependent ion channel activity in Xenopus oocytes. Virology, 412, 1, 83-90.
2010 Gowans, E., Roberts, S., Jones, K., Dinatale, I., Latour, P., Chua, B. ... Jackson, D. (2010). A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. Journal of Hepatology, 53, 4, 599-607.
2009 Li, S., Floess, S., Hamann, A., Gaudieri, S., Lucas, A., Hellard, M. ... Gowans, E. (2009). Analysis of FOXP3+ regulatory T cells that display apparent viral antigen specificity during chronic hepatitis C virus infection. PLoS Pathogens, 5, 12, 1000707-1-1000707-13.
2009 Meshkat, Z., Audsley, M., Beyer, C., Gowans, E. & Haqshenas, G. (2009). Reverse genetic analysis of a putative, influenze virus M2 HXXXW-like motif in the p7 protein of hepatitis C virus. Journal of Viral Hepatitis, 16, 3, 187-194.
2009 Martyn, J., Cardin, A., Wines, B., Cendron, A., Li, S., MacKenzie, J. ... Gowans, E. (2009). Surface display of IgG Fc on baculovirus vectors enhances binding to antigen-presenting cells and cell lines expressing Fc receptors. Archives of Virology, 154, 7, 1129-1138.
2008 Chua, B., Eriksson, E., Brown, L., Zeng, W., Gowans, E., Torresi, J. & Jackson, D. (2008). A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection. Vaccine, 26, 37, 4866-4875.
2008 Woollard, D., Haqshenas, G., Dong, X., Pratt, B., Kent, S. & Gowans, E. (2008). Virus-specific T-cell immunity correlates with control of gb virus b infection in marmosets. Journal of Virology, 82, 6, 3054-3060.
2008 Li, S., Gowans, E., Chougnet, C., Plebanski, M. & Dittmer, U. (2008). Natural Regulatory T Cells and Persistent Viral Infection. Journal of Virology, 82, 1, 21-30.
2008 Jones, K., Brown, L., Eriksson, E., Ffrench, R., Latour, P., Loveland, B. ... Gowans, E. (2008). Human dendritic cells pulsed with specific lipopeptides stimulate autologous antigen-specific T cells without the addition of exogenous maturation factors. Journal of Viral Hepatitis, 15, 10, 761-772.
2007 Chin, R., Earnest-Silveria, L., Koeberlain, B., Franz, S., Zentgraf, H., Dong, X. ... Torresi, J. (2007). Modulation of MAPK pathways and cell cycle by replicating hepatitis B virus: Factors contributing to hepatocarcinogenesis. Journal of Hepatology, 47, 3, 325-337.
2007 Haqshenas, G., Mackenzie, J., Dong, X. & Gowans, E. (2007). Hepatitis C virus p7 protein is localized in the endoplasmic reticulum when it is encoded by a replication-competent genome. Journal of General Virology, 88, 1, 134-142.
2007 Haqshenas, G., Dong, X., Ewart, G., Bowden, S. & Gowans, E. (2007). A 2a/1b full-length p7 inter-genotypic chimeric genome of hepatitis C virus is infectious in vitro. Virology, 360, 1, 17-26.
2007 Jones, K., Drane, D. & Gowans, E. (2007). Long-term storage of DNA-free RNA for use in vaccine studies. Biotechniques, 43, 5, 675-681.
2007 Haqshenas, G., Dong, X., Netter, H., Torresi, J. & Gowans, E. (2007). A chimeric GB virus B encoding the hepatitis C virus hypervariable region 1 is infectious in vivo. Journal of General Virology, 88, 3, 895-902.
2007 Martyn, J., Dong, X., Holmes-Brown, S., Pribul, P., Li, S., Drummer, H. & Gowans, E. (2007). Transient and stable expression of the HCV envelope glycoproteins in cell lines and primary hepatocytes transduced with a recombinant baculovirus. Archives of Virology, 152, 2, 329-343.
2007 Li, S., Jones, K., Woollard, D., Dromey, J., Paukovics, G., Plebanski, M. & Gowans, E. (2007). Defining target antigens for CD25⁺FOXP3⁺IFN-γ⁻ regulatory T cells in chronic hepatitis C virus infection. Immunology and Cell Biology, 85, 3, 197-204.
2006 Dong, X., Premkumar, A., Haqshenas, G., Gage, P. & Gowans, E. (2006). Amantadine inhibits the function of an ion channel encoded by GB virus-B but fails to inhibit virus replication. Journal of Clinical Virology, 36, S113-S113.
2005 Jackson, D., Deliyannis, G., Eriksson, E., Dinatale, I. & Gowans, E. (2005). Dendritic Cell Immunotherapy of Hepatitis C Virus Infection: Toxicology of Lipopeptide-Loaded Dendritic Cells. International Journal of Peptide Research and Therapeutics, 11, 4, 223-235.
2005 Mijch, A., Sasadeusz, J., Hellard, M., Dunne, M., McCaw, R., Bowden, S. & Gowans, E. (2005). A study to investigate the impact of the initiation of highly active antiretroviral therapy on the hepatitis C virus viral load in HIV/HCV-coinfected patients. Antiviral Therapy, 10, 2, 277-284.
1997 Atkins, G., Qiao, M., Coombe, D., Gowans, E. & Ashman, L. (1997). Hepatitis B virus binding to leucocyte plasma membranes utilizes a different region of the preS1 domain to the hepatocyte receptor binding site and does not require receptors for opsonins.. Immunology and Cell Biology, 75, 3, 259-266.
1996 Beardsley, A., Gowans, E., Burrell, C. & Marmion, B. (1996). Enhanced amplification of hepatitis C virus (HCV) cDNA by PCR: Detection of HCV RNA in archival sera. Journal of Clinical Microbiology, 34, 6, 1581-1582.
1996 Blight, K., Trowbridge, R. & Gowans, E. (1996). Absence of double-stranded replicative forms of HCV RNA in liver tissue from chronically infected patients. Journal of Viral Hepatitis, 3, 1, 29-36.

Book Chapters

Year Citation
2000 Burrell, C., Chisari, F., Gerlich, W., Gowans, E., Howard, C., Kann, M. & Marion, P. (2000). Taxomic Structure of the Family. In M. H. V. van Regenmortel, C. M. Fauquet & D. H. L. Bishop (Eds.), Virus Taxonomy Classification and Nomenclature of Viruses (pp. 325-334). San Diego, USA: Academic Press.

Conference Items

Year Citation
2016 Tomusange, K., Wijesundara, D., Gummow, J., Gowans, E. & Grubor-Bauk, B. (2016). Mucosal vaccination with a live recombinant rhinovirus followed by intradermal DNA administration elicits protective HIV-specific immune responses. Conference on HIV Research for Prevention (HIV R4P). Chicago, IL.
2013 Loveland, B. E., Latour, P., Roberts, S. K., Gordon, A., Kemp, W., Kitson, M. ... Gowans, E. J. (2013). A Phase I clinical trial of cellular immunotherapy for persistent Hepatitis C infection. 4th Meeting of the Australia-Chinese-Association-for-Biomedical-Sciences-Inc (ACABS). Hangzhou, Peoples Republic of China.
Grants and Funding
2009-2011 A novel HCV vaccine

EJ Gowans, B Loveland


$151,000 pa
2009-2011 A new HCV cell therapy

EJ Gowans, SK Roberts, B Loveland


$164,749 pa
2008-2009 A replication defective vaccine strategy for HCV.

EJ Gowans, B Loveland, J Torresi, S Li

ACH2 $110,000 pa
2011-13 A vaccine for hepatitis C virus.

EJ Gowans, J Torresi, S Das

Australia-India Biotechnology Fund $100,000 pa
2012-2014 Mucosal immunity to HIV                                    

EJ Gowans, A Suhrbier, S Wesselingh

NHMRC  $188,000 pa
2012-13 Development of a cytolytic HCV vaccine  and a novel challenge model to test efficacy  E J Gowans, B Grubor-Bauk ACH2  $174,000
2014-15 DNA vaccine therapy for HCV   E J Gowans, I Roberts-Thomson, B Grubor-Bauk THRF  $300,000
2014 Optimisation of HCV vaccine design E J Gowans, B Grubor-Bauk THRF  $100,000
2014-16 A quadrivalent vaccine for hepatitis C  Joseph Torresi, E J Gowans   NHMRC $450,000
2015-16 Approaches to develop an effective HCV vaccine E J Gowans, J Torresi, S Das AISRF $200,000
2016-17 A DNA vaccine to induce protective neutralizing antibodies to the HIV Tat protein E J Gowans THRF $160,000
2017 A multigenotypic HCV DNA vaccine  E J Gowans, B Grubor-Bauk, D Wijesundara ACH2   $85,000
2016-2018 A DNA vaccine for Zika virus   

E J Gowans, B Grubor-Bauk, D Wijesundara

NFMRI   $293,880


Teaching and Supervision
1964 - 1969 Preparation of materials for medical and science student practical classes and for the preparation of demonstrations.
1972 - 1975 Part-time demonstrator and tutor, Napier College, Edinburgh, to teach Medical Microbiology in the Higher National Certificate Course.
1984 - 1988 Lecturer and demonstrator in Virology teaching programme provided by the Division of Medical Virology, IMVS, to Science, Dental and Medical Students in the University of Adelaide.
1988 - 1993 Formal appointment as Visiting Lecturer, Department of Microbiology and Immunology, University of Adelaide.  Responsible for organisation of Virology Honours course.
1994-1997 Honorary Reader, Department of Microbiology, University of Queensland.
1996-2002 Assoc. Professor, Department of Paediatrics, University of Queensland.
1997-2002 Adjunct Professor, Department of Microbiology, University of Queensland.
2003-2012 Honorary Professor, Dept of Microbiology, Monash University      
2009-   Honorary Professor, University of Adelaide.



Year Name Training / Current position
1987-91 Dr TB Macnaughton Co-supervised with Prof Chris Burrell. After Dr Macnaughton completed his PhD, he accepted a position as Research Fellow, with Dr Michael Lai, Univ of S California.  He then came back to work in my lab and moved to Brisbane with me in 1994.  He was awarded a NHMRC grant but returned to the Univ of S California in 1999.  He returned to Brisbane in 2002 as a Research Associate with the CRC for Diagnostic Technologies.  Dr Macnaughton has 26 publications, including 3 in J Virol in 2002.
1991-93 Dr M Qiao Primary supervisor.  r Qiao was trained in medicine in China and initially came to spend some time in my lab as a visiting scholar.  She returned to China for a short time then came back to Adelaide to complete her PhD with me.  She then worked with Professor Burrell for 1-2 years before completing the requirements for registration as a Pathologist. She was then employed as a Research Fellow with Dr Jake Liang in NIH Bethesda before returning to Adelaide to take up an appointment as a Senior Pathologist.  Dr Qiao has 14 publications.
1991-94 Dr K Blight Primary supervisor.  I supervised Dr Blight in her BSc (Hons) year and throughout her PhD. Dr Blight published 5 manuscripts from the results of her PhD project and then took up a position with Dr C Rice, WASU, St Louis.  She then moved to the Rockefeller Univ, NY with Dr Rice and remained in this position until 2001, when she was appointed to the Faculty of WASU, St Louis.  Dr Blight has published 32 manuscripts, including publications in Science and J Virol.
1991-94 Dr S Cole Primary supervisor.  Dr Cole studied aspects of the pathogenesis of HCV for her PhD      thesis. She published 2 manuscripts. She now has a position in the Garvan Institute, Sydney.
1993-95 Dr M Beard Primary supervisor.   supervised Michael throughout his BSc (Hons) and PhD studies. He moved to Brisbane from Adelaide with me to help establish the laboratory there.  On the completion of his PhD, Dr Beard accepted a position of Research Fellow with Professor Stan Lemon in the Univ of North Carolina and then moved with Professor Lemon to the Univ of Texas, Galveston.  He is currently a Senior Research Fellow, RAH, Adelaide, where he has established his own laboratory.  He has recently attracted funding from NHMRC and the SA Anti-Cancer Foundation, and has published 25 manuscripts.
1994-97 Dr Y Gong Primary supervisor.  Dr Gong published 3 manuscripts as a result of his PhD studies and then took up a Post-doctoral fellow position with Dr John Tavis in St Louis.  He then moved to a position with Viridae, in Vancouver where he is currently the Director of Virology and Molecular Biology and has his own laboratory.  He was then appointed to an Adjunct Professor position in the Univ of British Columbia.  Viridae was closed on the death of the owner and Dr Gong now has a senior position with GSK in Brussels. He has 10 publications.
1996-98 Dr M Mather Supervisor.  Dr Mather completed his PhD on the topic of peptide vaccines for HCV and then took up a post-doctoral position in Philadelphia.  He returned in 2000 to take up a position with Dr David Boyle, as a Research fellow, AAHL, Geelong.
1996-99 Dr T Harvey Primary supervisor. Dr Harvey completed her PhD studies in my laboratory and then accepted several post-doctoral positions in Brisbane before taking up her current position with Dr Alex Khromykh.  Recently, she has exploited the Kunjin replicon as a vaccine delivery vehicle. Dr Harvey has 9 publications. She took up a post-doctoral position in the University of Leeds, UK and returned to Australia in 2011.
1998-2000 Dr S Greive Primary supervisor.  Dr Greive studied aspects of the expression of HCV proteins in mammalian cells during her PhD and then took up a Post-doctoral position in the Univ of Oregon.  She has attracted funding from the American Heart Foundation and is in the process of developing her independence.  She has 3 publications from her PhD thesis and 2 additional publications from her post doctoral position.
1998-2001 Dr S Ward Primary supervisor.    Dr Ward completed his BSc(Hons) and PhD studies in my laboratory in Brisbane. He studied HCV vaccines for his PhD thesis and took up a position of Research Fellow, Univ Oxford with Dr Paul Klenerman, in August 2001.  He published 3 manuscripts as a result of his PhD studies, and has 8 publications since then. Dr Ward returned to Brisbane in 2005 to work with Dr Elizabeth Powell and in now established as a senior researcher.
1998-2001 Dr SS Takyar Co-supervisor. Dr Takyar completed his PhD in my laboratory in Brisbane and published 3 manuscripts which resulted from this work. He then took up a post-doctoral position with Professor Harry Noller in Santa Cruz and published a manuscript in Cell describing the results of these studies. He then moved to a clinical position in Buffalo, NY state and is currently a Senior Post-doctoral Fellow at Yale where he combines clinical duties with research into micro RNA. He has 7 publications.
2000-03 Dr D Li Primary supervisor.  Dr Li completed his PhD studies in laboratory in Melbourne, having initiated his studies in Brisbane.  His work examined the interaction between the HCV core protein and the HCV IRES. He published 3 manuscripts resulting from his thesis. Dr Li then accepted a post-doctoral position with Professor John Mills at Monash University and has added additional publications since then. He is now a Senior Research Officer with Dr John Aaskov at QUT in Brisbane.  Dr Li recently took up a position with Assoc Professor David Harrich in the Queensland Institute of Medical Research.
2004-09 Dr X Dong Supervisor. Dr Dong developed the GB virus-B model to infect marmosets as a surrogate model for HCV infection. He was an author on 7 publications which arose directly or indirectly from his work. He is currently a Research Officer in the Garvan Institute, Sydney.
2006-10 Dr Sook-San Wong Primary supervisor. Dr Wong investigated the mechanism of action of the Dengue virus M protein, and established an assay to examine ion channel inhibitors.  Dr Wong is currently a Post-doctoral Fellow at St Jude’s Medical Research Institute, Tenessee.
2007-11 Dr Ali Gorzin Primary supervisor. Dr Gorzin investigated the role of the HCV NS2 protein in synthesis of HCV particles and the morphogenesis of HCV virions.  He moved to a teaching role in Iran after he completed his thesis.
2010-13 Dr Tessa Gargett Primary supervisor.  Dr Gargett investigated mechanisms to improve the efficacy of DNA vaccination.  Initial studies focussed on improved delivery, but as the project evolved, it concentrated on the use of cytolytic cell technology to increase cross presentation of immunogens.
2011-14 Dr Tamsin Garrod Primary supervisor.  Dr Garrod investigated the immunogenicity of HIV proteins, co-expressed from a DNA vaccine with different forms of the natural immunogen, HSP70.
2008-2015 Dr Philippe Latour. Primary supervisor. Dr Latour investigated the potential of HCV-specific mRNA-transfected dendritic cells to improve the efficacy of dendritic cell immunotherapy.
2013-2016 Dr Khamis Tomusange Primary supervisor. Dr Tomusange examined the potential of recombinant human rhinoviruses as a vaccine for HIV in parallel with DNA vaccines encoding Gag and secreted Tat.


Masters Student Supervision
Date Name Project
1998-1999 Ms LM Mison Primary supervisor.  Detection of hepatitis G virus and identification of genotypes in Australian-Pacific population groups.
2010-2012 Mr Hugh Trahair Primary supervisor. Mr Trahair examined the efficacy of different suicide genes and their effect on the immunogenicity of HCV proteins encoded and delivered by DNA vaccines.
2013-2015 Mr Harshwardhan Jagdale.
Primary supervisor.  Mr Jagdale examined the potential of recombinant porcine adenoviruses as a vaccine delivery vector.
Ongoing PhD Student Supervision
Date Name Project
2012- Mr Jason Gummow Primary supervisor. Mr Gummow will examine the effect of suicide genes encoded by DNA vaccines for HCV.
2014 Mr Makutiro Masavuli Primary supervisor.  Mr Masavuli will develop DNA vaccines designed to elicit humoral and cell mediated immune responses simultaneously to HCV.
2015 Mr Zelalem Addis Primary supervisor.  Mr Addis will develop a novel challenge model in mice and pigs to evaluate the efficacy of experimental HCV vaccines


Supervision of Post-Doctoral Fellows

My philosophy is to encourage post-doctoral fellows to become independent, write grants to generate their own funds and eventually be in a position to establish their own laboratory.

Dr TB Macnaughton.   Dr Macnaughton worked with me after his return from a Post-doctoral position in the USA.  I encouraged his independence and he was awarded a NHMRC grant to study aspects of HDV.  He returned to work in the USA for approx 3 years to work in the CRC for Diagnostic Technologies in Brisbane.  As outlined above, Dr Macnaughton has 26 publications.
Dr R Trowbridge.    Dr Trowbridge joined my laboratory in 1992 and moved with me to Brisbane where she helped establish the laboratory in SASVRC.  Dr Trowbridge and I were awarded several NHMRC grants in the period 1994-98, until she decided to return to the UK.  Dr Trowbridge held a senior Post-doctoral fellowship in the Department of Microbiology, University of Leeds and is now employed by a biotechnology company in Yorkshire.  Dr Trowbridge has 15 publications, many of which were published from my laboratory, including the description of the cloning of the full-length HCV cDNA reported from my laboratory in 1998. 
Dr D Warrilow   Dr Warrilow joined my laboratory after completing a PhD with Prof R Symons.  He is a talented individual who established an in vitro assay for the BVDV polymerase.  On my departure from Brisbane, Dr Warrilow joined Queensland Health to study aspects of the Australia lyssavirus infection.  He successfully established his own laboratory and his independence.  More recently, he moved back into a more conventional research environment in the QIMR as a Senior Research Fellow and has published several manuscripts on HIV since then. He has 20 publications.
Dr M Linn   Dr Linn worked on dendritic cell purification and culture in a project that I supervised jointly with Dr A Nicol.  Although she is very talented, she was never quite able to develop her independence and when I moved to my present position in Melbourne, she moved back to the QIMR laboratory in which she had completed her PhD and has now taken up an administrative position in Queensland Health.
Dr H Netter  Dr Netter joined my laboratory in Brisbane to work on hepatitis D virus.  He developed a world-wide reputation for his work and was awarded a NHMRC grant in his own right.  Dr Netter was unable to sustain his work on HDV and on my suggestion, he developed an interest in hepatitis C virus. He was subsequently awarded another NHMRC grant to investigate the potential of novel recombinant HBsAg particles to elicit neutralising antibody to HCV.  Hans now has his own laboratory in the Dept of Microbiology, Monash University and we continue to collaborate.  He was awarded a new NHMRC grant in 2007 and is clearly now an independent researcher. He has 51 publications.
Dr W Lott   Dr Lott has a PhD in chemistry and joined my laboratory to provide complementary expertise.  Dr Lott already had several years post-doctoral experience and this quickly became evident during his time in my laboratory.  He was appointed to an honorary position in the Dept of Biochemistry, Univ of Queensland and supervised Dr S Takyar’s PhD project.  Dr Lott returned to the USA after I moved to Melbourne and established his own laboratory in the Univ of New Mexico.  Dr Lott has more recently re-established his laboratory in the Queensland University of Technology and has attracted funding from the Australian Centre for Hepatitis and HIV Virology.  We still collaborate and are in regular touch communication.   Dr Lott has10 publications including 4 which were the result of our work in Brisbane and these include manuscripts in PNAS, J Mol Biol and J Virol.
Dr J Martyn   Dr Martyn joined my laboratory in Melbourne in April, 2003.  He has used his expertise in molecular biology to develop a number of recombinant baculoviruses which can direct the expression of the recombinant protein in mammalian cells.  He has 9 publications and 2 patents, and contributed to a recent manuscript in J Virol.  His funding was not renewed for 2008, but he accepted a scientific position with CSL Ltd.
Dr K Jones.  Dr Jones completed her PhD studies in the Univ of NSW, Sydney and established the technology to purify dendritic cells in my laboratory.  She was seminal in the organisation of the NIH funded clinical trial. She published 4 manuscripts during her tenure in my laboratory in (2003-2008) but has currently forsaken science in favour of motherhood.
Dr G Haqshenas.   Dr Haqshenas joined my laboratory in November, 2003 and rapidly proved his versatility and expertise.  He is experienced in handling RNA viruses. He contributed widely to projects in the laboratory and demonstrated his growing independence by the publication of three major studies of HCV replication. He now has 16 publications. Dr Haqshenas is a co-chief investigator on a NHMRC grant held by me and is the senior investigator on a recent ACH2 grant in aid, with Dr Woollard and me. Dr Haqshenas is co-supervisor of PhD students Wong, Gorzin and Gouklani. He left my laboratory in mid-2008 and has been unable to secure funding since then.
Dr D Woollard.       Dr Woollard completed his PhD studies in the University of Melbourne in 2000 and then spent 3½ years as a post-doctoral fellow in the laboratory of Dr Chris Walker, Columbus, before joining my laboratory in March, 2004.  Dr Woollard has 11 publications, including manuscripts in Science and Hepatology.  He was a co-chief investigator on an ACH2 grant from ACH2, but has failed to generate funding for 2008 and subsequently accepted a regulatory position with CSL. He is currently studying towards an MBA.
Dr Shuo Li      Dr Li joined my laboratory in March 2005 and made an immediate impact as a free thinking immunologist.  Dr Li previously worked in the area of regulatory T cells in allergy and is planning to apply her expertise and knowledge to regulatory T cells in HCV infection. She has recently published a seminal manuscript on the detection of regulatory T cells in HCV infection. She wrote a grant application to NHMRC but as her track record was not strong, I was listed as CIA and the grant was funded from 2007-2009.
Dr Wes Black  Dr Black joined my laboratory in April, 2005 to investigate the potential of ion channel inhibitors to inhibit HCV replication.  He was an accomplished molecular biologist and applied his expertise to establishing a high throughput screening assay to examine chemical libraries for inhibitors of the HCV p7 protein function. He has 5 publications resulting from his PhD studies but he was unable to make an impact on his field of study and his contract was not renewed in 2007.
Dr Darren Miller   Dr Miller joined my new laboratory in the WCHRI early in 2009.  He is an experienced virologist whose strengths are in animal experimentation.  He supervised much of the molecular biology that was performed in the laboratory in 2009-10 and synthesised a number of different DNA constructs for use in vaccine studies. He left the laboratory in January 2011 to accept a tenured position in the University of Adelaide.
Dr Branka Grubor-Bauk   Dr Grubor-Bauk also joined my laboratory in 2009. She is an experienced immunologist with specific expertise in NK cells. She plans to construct several different recombinant adenoviruses, based on the human adenovirus type 5 or the porcine adenovirus type 3.
Dr Satish Dogra   Dr Dogra joined my laboratory in 2010. He is an experienced molecular virologist. His project was to develop the TET-ON/OFF system to permit inducible expression of suicide genes in vaccinated animals.  He was only employed for one year as funds were unavailable to employ him for longer.
Dr Stanley Yu    Dr Yu is a talented molecular biologist who joined my laboratory in March 2011.  He quickly showed that his skills complemented existing skills in the laboratory and is already a valuable member of staff. Lack of funds meant that I was unable to employ him in 2015, but I remain in close contact with him.
Dr Judy Li   Dr Li is also a talented molecular biologist who joined my laboratory in June, 2013.  She is expert in the design and synthesis of recombinant adenoviruses vectors.  She was forced to leave my laboratory due to lack of funding.
Dr Danushka Wijesundara  Dr Wijesundara joined my laboratory in April, 2014.  He is a talented immunologist with specific expertise in HIV vaccine design and analysis.  He has rapidly settled into his role and is now an important member of the group.



Date Role Membership Country
2014 - ongoing Virus Research
1999 - ongoing Journal of Gastroenterology and Hepatology
1998 - ongoing Virus Genes

Committee Memberships

Date Role Committee Institution Country
2015 - ongoing Member NHMRC Grant Assigner’s Panel
2012 - ongoing Chair Strategic Research Directions Committee Basil Hetzel Institute, The Queen Elizabeth Hospital
2012 - ongoing Member Microbiology Grant Review Panel NHMRC
2012 - 2014 Member Advisory Committee for Biologicals, Therapeutic Goods Administration
2012 - ongoing Member BHI Policy Committee
2012 - ongoing Member Local organising committee Australian-Pacific Congress of Virology
2005 - ongoing Chair Institutional Biosafety Committee The Queen Elizabeth Hospital and Basil Hetzel Institute Australia


Date Institution Department Organisation Type Country
2012 - ongoing Viralytics Ltd
NHMRC Senior Research Fellow
The Queen Elizabeth Hospital
QEH - Basil Hetzel Bldg
Org Unit
Surgical Specialties